Amarin Sinks to Five-Month Low After Losing Ruling on Heart Drug

Sept. 3, 2020, 8:28 PM

Amarin Corp. fell to the lowest since March after it lost its bid to revive patents on the heart medicine Vascepa, its only product, a decision that opens the door to generic competition for the drug.

The U.S. Court of Appeals for the Federal Circuit in Washington affirmed a trial court ruling that invalidated six patents on Vascepa. The decision, made without a formal opinion, came just one day after the court heard arguments in the case.

Amarin closed down 9.5% in New York trading of 47 million shares, seven times the daily average. The stock has shed more than ...

To read the full article log in. To learn more about a subscription click here.